Prescription drug · ANDA
Deflazacort Oral Suspension (Deflazacort) NDC 81806-200
Deflazacort 22.75 mg/mL · Suspension · Oral · Doppel Farmaceutici S.r.l.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 81806-200-73 | 8180602007381806020073 | 1 BOTTLE in 1 CARTON (81806-200-73) / 13 mL in 1 BOTTLEMarketed from Oct 23, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Deflazacort Oral Suspension
- Generic name (nonproprietary)
- deflazacort
- Active ingredients
- Deflazacort — 22.75 mg/mL
- Dosage form
- Suspension
- Route
- Oral
- Labeler
- Doppel Farmaceutici S.r.l.NDC labeler code 81806
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 220042
- Marketing start
- Listing expires
- Other FDA classes
- Corticosteroid Hormone Receptor Agonists (Mechanism)
- Identifiers
- Product ID 81806-200_57c38c16-099f-a6e0-e063-6294a90a2304SPL ID 57c38c16-099f-a6e0-e063-6294a90a2304SPL set ID 40a833a4-e029-a99e-e063-6394a90afd50RxCUI 1870964UNII KR5YZ6AE4BUPC 0370710200732
- Pharmacologic class
- Corticosteroid
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N481806020073followed by a unit qualifier and the quantityPackage 81806-0200-73. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Deflazacort oral suspension is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. Deflazacort oral suspension is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 81806-200
- What is NDC 81806-200?
- 81806-200 is the product NDC for Deflazacort Oral Suspension (deflazacort), Deflazacort 22.75 mg/mL suspension, listed with the FDA by Doppel Farmaceutici S.r.l.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Deflazacort Oral Suspension (Deflazacort).
- What is the active ingredient?
- Deflazacort.
- Who is the labeler?
- Doppel Farmaceutici S.r.l., NDC labeler code 81806. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Deflazacort Oral Suspension?
- 4 other product NDCs are listed under this name. See all Deflazacort Oral Suspension NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Deflazacort Oral Suspension products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Deflazacort Oral Suspensiondeflazacort oral | Deflazacort 22.75 mg/mL | SuspensionOral | Biocon Pharma Inc. | 70377-188 | 70377-0188-21 |
| Deflazacort Oral Suspensiondeflazacort oral | Deflazacort 22.75 mg/mL | SuspensionOral | Sun Pharmaceutical Industries, Inc. | 57664-993 | 57664-0993-01 |
| Deflazacort Oral Suspensiondeflazacort | Deflazacort 22.75 mg/mL | SuspensionOral | Zydus Pharmaceuticals (USA) Inc. | 70710-2007 | 70710-2007-03 |
| Deflazacort Oral Suspensiondeflazacort oral | Deflazacort 22.75 mg/mL | SuspensionOral | Cranbury Pharmaceuticals, LLC | 27808-249 | 27808-0249-01 |
Other NDCs under ANDA 220042
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Deflazacort Oral Suspensiondeflazacort | Deflazacort 22.75 mg/mL | SuspensionOral | Zydus Pharmaceuticals (USA) Inc. | 70710-2007 |
| JAYTHARI Oral Suspensiondeflazacort | Deflazacort 22.75 mg/mL | SuspensionOral | Zydus Pharmaceuticals (USA) Inc. | 70710-2131 |
| JAYTHARI Oral Suspensiondeflazacort | Deflazacort 22.75 mg/mL | SuspensionOral | Doppel Farmaceutici S.r.l. | 81806-213 |